Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 3/20 | 0.52 |
| ▸ | CYP11B2 | P19099 | 10/20 | 0.46 |
| ▸ | BMP4 | P12644 | 1/20 | 0.45 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2594102 | 0.80 | CYP11B2 (0.52) | CYP17A1CYP11B2PRKCZCYP11B1EGFR | |
| SCHEMBL2587151 | 0.76 | CYP17A1 (0.46) | CYP17A1CYP11B2PRKCZCYP11B1EGFR | |
| SCHEMBL1367994 | 0.76 | BMP4 (0.45) | CYP17A1BMP4JAK1PIK3C3 | |
| SCHEMBL20873066 | 0.75 | PRKCZ (0.64) | CYP17A1CYP11B2PRKCZCYP11B1CYP3A4 | |
| SCHEMBL2594943 | 0.73 | CYP17A1 (0.56) | CYP17A1CYP1A2 | |
| SCHEMBL1202802 | 0.71 | CDK2 (0.45) | BMP4JAK1PIK3C3LRRK2 | |
| SCHEMBL2593791 | 0.71 | CYP17A1 (0.63) | CYP17A1CYP11B2PRKCZCYP11B1CYP1A2 | |
| SCHEMBL20873077 | 0.70 | CYP1A2 (0.57) | CYP17A1BMP4PRKCZCYP1A2KCNA5 | |
| SCHEMBL2591159 | 0.69 | CYP17A1 (0.51) | CYP17A1BMP4CYP11B1CYP3A4CYP1A2 | |
| SCHEMBL4562594 | 0.69 | CYP17A1 (1.00) | CYP17A1CYP11B1CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145419-B2 | Imidazopyridazinyl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145419-B2 | Imidazopyridazinyl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145419-B2 | Imidazopyridazinyl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-09-29 | — | — | US | disclosed |
| EP-2563792-B1 | IMIDAZOPYRIDAZINYL COMPOUNDS AND THEIR USES FOR CANCER | BRISTOL MYERS SQUIBB CO (US) | 2014-08-27 | — | — | EP | disclosed |
| EP-2563792-B1 | IMIDAZOPYRIDAZINYL COMPOUNDS AND THEIR USES FOR CANCER | BRISTOL MYERS SQUIBB CO (US) | 2014-08-27 | — | — | EP | disclosed |
| CN-102971326-A | Imidazopyridazinyl compounds and their uses for cancer | BRISTOL MYERS SQUIBB CO | 2013-03-13 | — | — | CN | disclosed |
| EP-2563792-A1 | IMIDAZOPYRIDAZINYL COMPOUNDS AND THEIR USES FOR CANCER | Bristol-Myers Squibb Company (US) | 2013-03-06 | — | — | EP | disclosed |
| US-20130045980-A1 | IMIDAZOPYRIDAZINYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-21 | — | — | US | disclosed |
| US-20130045980-A1 | IMIDAZOPYRIDAZINYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-21 | — | — | US | disclosed |
| US-20130045980-A1 | IMIDAZOPYRIDAZINYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-21 | — | — | US | disclosed |
| WO-2011137155-A1 | IMIDAZOPYRIDAZINYL COMPOUNDS AND THEIR USES FOR CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-03 | — | — | WO | disclosed |
| WO-2011137155-A1 | IMIDAZOPYRIDAZINYL COMPOUNDS AND THEIR USES FOR CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045980-A1 | IMIDAZOPYRIDAZINYL COMPOUNDS | CYP2C19, CYP3A7, CYP2C18 | CYP17A1 54/4885CYP11B2 45/4885BMP4 3862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.